Drug Combination Details
| General Information of the Combination (ID: C34194) | |||||
|---|---|---|---|---|---|
| Name | Elemene NP Info | + | Rapamycin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | FTC-133 | CVCL_1219 | Thyroid gland follicular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The novel combination of mTOR inhibitor with Beta-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combinatorial Antitumor Effect of Rapamycin and Beta-Elemene in Follicular Thyroid Cancer Cells. Biomed Res Int. 2016;2016:6723807. | |||
